Lung Cancer
Covers genes with direct therapeutic implications for 20 targeted drugs, including those recommended in the latest NCCN guidelines.
About
DIPLOIDE is dedicated to utilizing genomics in order to advance precision medicine for cancer. DIPLOIDE’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
DIPLOIDE’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported (except for the Sentis Colorectal Cancer Panel for which a liquid biopsy version is still being developed).
DIPLOIDE’s lung cancer panel covers 11 genes with direct therapeutic implications for 20 targeted drugs, including those recommended in the latest NCCN guidelines. The panel detects all classes of genomic alterations including SNV, CNV, InDels and Fusion using routine FFPE samples, tumor tissue, DNA or peripheral blood.
Benefits
-
Comprehensive: complete exome plus covered flanking intronic regions for all genes tested; A single assay that detects point mutations, deletions, insertions, duplications, rearrangements.
-
Robust: Clinically important variants (pathogenic or likely pathogenic) are verified by Sanger sequencing, while qPCR verifies large genetic rearrangements.
-
Convenient: blood or saliva tests; DNA is also accepted.
-
Professional: the latest generation variant database guarantees up-to-date analysis and interpretation.
